GLAXOSMITHKLINE LICENSES SECOND HUMAN GENOME DRUG

Thursday morning, GlaxoSmithKline (nyse: GSK -- news -- people ) exercised its right to co-develop and co-promote HGS-ETR1, a cancer drug developed by Human Genome Sciences (nasdaq: HGSI -- news -- people) that is being developed to treat non-Hodgkins lymphoma, non-small cell lung cancer, and colorectal cancer. Previously, Glaxo had exercised a similar right to co-develop LymphoStat-B, for lupus and rheumatoid arthritis.

Forbes (http://www.forbes.com/markets/2005/08/18/glaxosmithkline-human-genome-0818markets06.html)